51 completed, 21 terminated, 12 active not recruiting, 12 recruiting. 85 Phase 1, 36 Phase 2, 4 Early Phase 1, 3 Not applicable.
Follow poly ICLC: new trials by email Literature Review of poly ICLC trials Research Report on poly ICLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients Paclitaxel, Carboplatin, Pembrolizumab - Triple Negative Breast Cancer | Phase 1 | Not yet recruiting | Washington University School of Medicine | 30 | 2026-10-01 | 2026-09-04 |
| A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) DNAJB1-PRKACA Peptide Vaccine, DRP-104, Nivolumab - Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 27 | 2026-10-01 | 2026-10-05 |
| An Experimental Medicine Multicenter Trial to Evaluate the Safety and Immunogenicity of Experimental Versus Authorized SARS-CoV-2 Vaccine Candidates as a Booster Dose in Healthy Participants Previously Vaccinated With Authorized mRNA SARS-CoV-2 Vaccines. CD40.RBDv vaccine adjuvanted with Hiltonol®, CD40.Pan.CoV vaccine adjuvanted with Hiltonol®, Comirnaty® vaccine - Healthy Adults | Early Phase 1 | Recruiting | ANRS, Emerging Infectious Diseases | 48 | 2026-05-13 | 2026-06-02 |
| Dose Escalation Trial of CD40.Pan.CoV Vaccine, Adjuvanted or Not, as a Booster in Adult Healthy Volunteers CD40.Pan.CoV Low dose(0.25mg), CD40.Pan.CoV Low dose (0,25mg) adjuvanted with Hiltonol®, CD40.Pan.CoV High dose (1mg) - Healthy Volunteers | Phase 1 / Phase 2 | Active not recruiting | ANRS, Emerging Infectious Diseases | 48 | 2025-06-18 | 2026-05-05 |
| Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer AGEN2373, Balstilimab, Cyclophosphamide - Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 38 | 2025-05-27 | 2025-12-03 |
| Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC) mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)], Durvalumab, Tremelimumab - Biliary Tract Cancers | Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 25 | 2025-05-27 | 2026-05-08 |
| Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease Synthetic long peptide personalized cancer vaccine, Poly ICLC, Signatera or Altera testing - Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma | Phase 1 | Recruiting | Washington University School of Medicine | 64 | 2025-03-20 | 2026-09-21 |
| Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant Dendritic Cell Tumor Peptide Vaccine, Ipilimumab, Leukapheresis - Diffuse Hemispheric Glioma, H3 G34-Mutant | Phase 1 | Withdrawn | Jonsson Comprehensive Cancer Center | 2024-12-01 | 2025-02-24 | |
| KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer KRAS Vaccine with Poly-ICLC adjuvant, Balstilimab, Botensilimab - Colorectal Cancer, Pancreatic Cancer | Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 54 | 2024-11-04 | 2026-07-31 |
| A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma Biospecimen Collection, Dendritic Cell Therapy, Leukapheresis - Diffuse Hemispheric Glioma, H3 G34-Mutant | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 6 | 2024-06-14 | 2026-02-17 |
| Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC Poly ICLC, IVIG - Stage IV NSCLC | Phase 1 / Phase 2 | Withdrawn | VA Office of Research and Development | 2024-06-04 | 2024-09-19 | |
| Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ MUC1 Peptide Vaccine, Hiltonol®, Aromatase Inhibitor - Ductal Carcinoma in Situ | Phase 1 | Recruiting | Finn, Olivera, PhD | 50 | 2024-02-07 | 2026-10-16 |
| Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance Poly-ICLC intramuscular (IM) injection, Poly-ICLC, Intertumoral (IT) injection - Prostate Cancer Patients on Active Surveillance | Phase 2 | Recruiting | Ashutosh Kumar Tewari | 114 | 2024-01-16 | 2024-04-02 |
| ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine, Hiltonol - Glioma, Malignant | Phase 1 | Active not recruiting | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | 24 | 2023-08-30 | 2026-04-30 |
| Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer Neoantigen Vaccine with Poly-ICLC adjuvant, Retifanlimab - Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic | Phase 1 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2023-05-03 | 2023-05-09 | |
| Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm Peptide-based vaccine, Poly ICLC - Myelofibrosis, Essential Thrombocythemia | Phase 1 | Active not recruiting | Marina Kremyanskaya | 7 | 2023-04-04 | 2026-09-28 |
| In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Poly ICLC, Radiation Therapy - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 | Active not recruiting | University of Southern California | 14 | 2023-01-09 | 2026-06-18 |
| Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery Optimized neoantigen synthetic long peptide vaccine, Poly-ICLC - Pancreas Cancer, Pancreatic Cancer | Phase 1 | Completed | Washington University School of Medicine | 33 | 2022-12-15 | 2026-05-06 |
| Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors Personalized Neoantigen Peptide Vaccine with Poly-ICLC and Checkpoint Inhibitors - Cancer, Solid Tumor, Adult | Phase 1 / Phase 2 | Completed | Seqker Biosciences, Inc. | 8 | 2022-11-24 | 2026-07-24 |
| Neoantigens Phase I Trial in Newly Diagnosed Glioblastoma Patients NeoPep Vaccine1 plus Poly-ICLC, NeoPep Vaccine2 plus Poly-ICLC - Glioma, Malignant, Antigen-specific Vaccines | Not applicable | Unknown | Shanghai 10th People's Hospital | 10 | 2022-09-13 | 2022-10-12 |
Showing 20 of 109. Sign in to see all of them.
Melanoma (21) · Glioblastoma (12) · Breast Neoplasms (10) · Neoplasms (10) · Carcinoma, Non-Small-Cell Lung (9) · Pancreatic Neoplasms (9) · Glioma (8) · Ovarian Neoplasms (7) · Colonic Neoplasms (5) · Prostatic Neoplasms (5) · Squamous Cell Carcinoma of Head and Neck (5) · Triple Negative Breast Neoplasms (5) · Astrocytoma (4) · Carcinoma (4) · Fallopian Tube Neoplasms (4)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (11) · Washington University School of Medicine (10) · Nina Bhardwaj (5) · Ashutosh Kumar Tewari (3) · BioNTech US Inc. (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · Jonsson Comprehensive Cancer Center (3) · Ludwig Institute for Cancer Research (3) · National Cancer Institute (NCI) (3) · Rockefeller University (3) · Roswell Park Cancer Institute (3) · ANRS, Emerging Infectious Diseases (2) · Celldex Therapeutics (2) · Craig L Slingluff, Jr (2) · Ian F. Pollack, M.D. (2)
United States (93) · Spain (3) · Switzerland (3) · France (2) · United Kingdom (2) · Australia (1) · Canada (1) · China (1) · Denmark (1) · Germany (1) · Hungary (1) · Netherlands (1) · Poland (1) · Puerto Rico (1) · Russia (1)
Nina Bhardwaj, MD, PhD (8) · Nilofer Azad, MD (4) · Mark DeMario, MD (3) · Elizabeth Griffiths (2) · Frank Lieberman, MD (2) · James Felker, MD (2) · Joshua Brody, MD (2) · Kenneth G Lucas, MD (2) · Marina Baretti, MD (2) · Marina Caskey, MD (2) · Pierre-Yves Dietrich, Professor (2) · Sujit S Nair, Ph.D. (2) · William E Gillanders, M.D. (2) · Aaron Rapoport, M.D. (1) · Adilia Hormigo, MD, PhD (1)
PMID 20615924, PMID 23032745, PMID 110688, PMID 11440640, PMID 16011702, PMID 16051812, PMID 16625202, PMID 18073382, PMID 18778201, PMID 18797818, PMID 18850068, PMID 19355966, PMID 19420084, PMID 19564349, PMID 20038196, PMID 20389020, PMID 20549206, PMID 21467219, PMID 22065672, PMID 22086194, PMID 22379685, PMID 24520093, PMID 24739759, PMID 24777970, PMID 24792486, PMID 24801836, PMID 24888813, PMID 25424847, PMID 26564103, PMID 26870818, PMID 27956136, PMID 28158275, PMID 28388966, PMID 29157306, PMID 29344432, PMID 29696308, PMID 29950349, PMID 30110645, PMID 30611774, PMID 30753611, PMID 31024557, PMID 31214178, PMID 31699709, PMID 31986264, PMID 32125452, PMID 32134116, PMID 32298247, PMID 32574262, PMID 32819975, PMID 32998157
P30CA016056 (2), R21CA133859 (2), 2016 (1), K08CA248624 (1), P01CA247886 (1), P30CA015704 (1), P50CA062924 (1), P50CA190991 (1), P50CA196510 (1), R01CA187219 (1), R01CA296410 (1), R21AI110736 (1), R21CA233856 (1), R44CA183075 (1), U01CA062399 (1)